Proton-pump inhibitor use and the development of new ischemic heart disease in non-cardiac chest pain patients.
Yeseong D KimStephen GanocyRonnie FassPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2020)
PPIs confer a statistically significant, but marginal effect on the risk of IHD development in NCCP patients. Thus, PPI use in NCCP only minimally alters the overall benign natural course of the disease.